A Recap of PropThink’s Week in Biotech
Most Popular - We offered some insight this week into how social media can drive the markets. Jason Napodano noted recent performance from SRPT, and discussed what patient-investor … Continue Reading
Read nowSearch Results for achn
Does Achillion Have a Place in the HCV Market of the Future?
Long Ideas - The biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation … Continue Reading
Read nowGilead and the Pharmasset Deal: Do the Ends Justify the Means?
Research - In November of 2011, Gilead announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO … Continue Reading
Read nowBioCryst, Presidio Merger Creates Yet Another Competitor in the HCV Segment
Quick Picks - In an all-stock merger announced Thursday morning, BioCryst Pharmaceuticals (NASDAQ:BCRX) will acquire privately-held Presidio, Inc, creating a new business entity to focus on oral Hepatitis … Continue Reading
Read nowAbbot’s Impressive HCV Data Continues the Trend; Everyone’s Got a Candidate
Long Ideas - Developers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that … Continue Reading
Read nowA Glance At This Week's Top Healthcare Stories
Recap - Shares of HEB furtively peaked on Monday following an announcement that Ampligen’s advisory committee meeting date had been set, but shares were unsuccessful in maintaining … Continue Reading
Read nowVertex Drops One Drug, Advances Another as HCV Segment Heats Up
Long Ideas - On Tuesday, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that while it would be advancing its developmental Hepatitis C (HCV) treatment, ALS-2200, into Phase II testing, ALS-2158 didn’t … Continue Reading
Read now